Dr Srinivasan had enlightened all of us on the research over diabetic as pill form to day Thank u sir And a you tube show is added as my might to know what is is. K R IRS 20326 https://youtu.be/eYDVPmNDTeI GILA Monster
On Fri, 20 Mar 2026 at 07:54, srinivasan mani <[email protected]> wrote: > My humble contribution to this discussion. > The research into the development of oral form of Insulin is progressing. > However the major brake through in the treatment of Diabetes is the > development of GLP 1 or (Glucacon like peptide ) agonists. > The history of development of this class of drugs is indeed fascinating. > In the 90s they were impressed observing the eating habits of Gilla desert > monsters a form of Reptiles in the southwest of USA. These reptiles would > eat only occasionally, but can survive long . So they studied the venom of > these Gilla monsters and , it turned out the venom had this chemical called > Exendin and it’s mode of action was Enhancing the GLP receptors. This > subsequently led to the development of the popular Ozempic, Wygovy etc., > now available. They control Diabetes and in addition they help people loose > weight as well. The reason for that is , this class of drugs decrease the > gastric motility and resulting in early satiety (or a feeling of fullness > of stomach). > There are some not too serious side effects. Now this has been the ultra > major development in the management of Diabetes. > In addition there is another class of oral drugs SGLT inhibitors act > differently also has helped control Diabetes, in particular to prevent > Kidney from Diabetes. > So there has been considerable excitement now in achieving better control > of the sugar in addition to preventing complications. > > Just a few ‘pearls ‘ from my limited knowledge of medicine. > Srinivasan S Mani MD > > Get Outlook for iOS <https://aka.ms/o0ukef> > ------------------------------ > *From:* [email protected] < > [email protected]> on behalf of Rajaram > Krishnamurthy <[email protected]> > *Sent:* Thursday, March 19, 2026 9:51:32 PM > *To:* APS Mani <[email protected]> > *Cc:* Chittanandam V R <[email protected]>; YM < > [email protected]>; Dr Sundar <[email protected]>; Ravi mahajan < > [email protected]>; Venkat Giri <[email protected]>; > SRIRAMAJAYAM <[email protected]>; Rangarajan T.N.C. < > [email protected]>; Srinivasan Sridharan <[email protected]>; > Mathangi K. Kumar <[email protected]>; Venkat Raman < > [email protected]>; Rama <[email protected]>; Kerala Iyer < > [email protected]>; Societyforservingseniors < > [email protected]>; thatha patty < > [email protected]>; Sanathana group < > [email protected]> > *Subject:* Re: diabetic news > > That is real strength and determination to counter the drawback. Pranam > KR IRS 20326 > > On Fri, 20 Mar 2026 at 05:56, APS Mani <[email protected]> wrote: > > I am glad that under the 'reference' most are Japanese. In Japan, they > have a systematic schedule to get rid of diabetes. I tried there for four > decades but did not succeed. Back in my village for more than a decade > now, I have been free from insulin injection for the last three months. A > humble effort on diet, routine stretching, and simple exercises fitting to > my present age. Happy, Mani > > On Thu, Mar 19, 2026 at 1:57 PM Rajaram Krishnamurthy < > [email protected]> wrote: > > A new peptide-based drug-delivery strategy may bring scientists closer to > an oral form of insulin. > > For more than 100 years, scientists have pursued the idea of delivering > insulin as a pill. This goal has remained difficult to achieve because > insulin breaks down in the digestive system and the intestine lacks a > natural transport pathway that allows the hormone to enter the bloodstream. > > Because of these biological barriers, many people with diabetes still > depend on daily insulin injections, which can place a significant burden on > long-term treatment and quality of life. > > Researchers at Kumamoto University, led by Associate Professor Shingo Ito, > have now developed a promising drug delivery strategy designed to overcome > these obstacles. Their approach uses a cyclic peptide that can pass through > the small intestine. The molecule, called the DNP peptide, helps insulin > move across the intestinal barrier and into the body after oral > administration. > > Two Complementary Strategies for Oral Delivery > > The researchers established two effective approaches to facilitate the > intestinal absorption of insulin: > > Mixing method (interaction-based): In this approach, a modified “D-DNP-V > peptide” was mixed with zinc-stabilized insulin hexamers. When given orally > in several diabetes models, including chemically induced (STZ mice) and > genetic (Kuma mice) models, the treatment quickly lowered blood glucose > levels to the normal range. With once-daily dosing, stable glycemic control > was maintained for three straight days. > > Conjugation method (covalent-based): In the second approach, the team used > click chemistry to directly attach the DNP peptide to insulin, creating a > “DNP–insulin conjugate.” This version produced glucose-lowering effects > similar to those seen with the mixing method, supporting the idea that the > peptide actively drives intestinal transport of insulin. > > Overcoming the Dose Barrier > > One of the biggest challenges in developing oral insulin has been the need > for very large doses, often more than ten times the amount used in an > injection. In contrast, this platform reached a pharmacological > bioavailability of about 33–41% compared with subcutaneous injection. > > That finding suggests a major reduction in the amount of insulin required > for oral use and represents an important step toward real-world clinical > application. > > DNP Peptide Based Delivery Platform May Support Future Oral Insulin > Development > > Engineered DNP peptides—either fused to insulin-binding peptides or > covalently linked to insulin using click chemistry—directly enhanced > insulin absorption in mice. These findings demonstrate that DNP peptides > are versatile carriers for the oral delivery of macromolecular drugs, > offering a practical way to convert injectable biopharmaceuticals into > patient-friendly oral medicines. Credit: Chikamatsu et al. > > Perspective > > “Insulin injections remain a daily burden for many patients,” said > Associate Professor Shingo Ito. “Our peptide-based platform offers a new > route to deliver insulin orally and may be applicable to long-acting > insulin formulations and other injectable biologics.” > > The findings were published in the international journal Molecular > Pharmaceutics. > > The research team is now moving forward with translational studies. > Planned work includes testing the system in large animal models and > evaluating its performance in human intestinal systems. > > Reference: “Small Intestine-Permeable Cyclic Peptide-Based Technology > Enables Efficient Oral Delivery and Glycemic Efficacy of Zinc-Stabilized > Insulin Hexamer and Its Analogs in Diabetic Mice” by Shoma Chikamatsu, > Kosei Sakaguchi, Masataka Michigami, Kimi Araki, Shoen Kume, Midori > Tokuyasu, Takeshi Masuda, Ikuo Fujii, Sumio Ohtsuki and Shingo Ito, 24 > November 2025, Molecular Pharmaceutics. > > KR IRS 19326 > > -- > You received this message because you are subscribed to the Google Groups > "Sanathana dharma and science" group. > To unsubscribe from this group and stop receiving emails from it, send an > email to [email protected]. > To view this discussion visit > https://groups.google.com/d/msgid/sanathana-dharma-and-science/CAL5XZopajyGp7r%2BydehMnWPVGb6-VjTe0Vr-TuruPVKW4kJ0Zg%40mail.gmail.com > <https://groups.google.com/d/msgid/sanathana-dharma-and-science/CAL5XZopajyGp7r%2BydehMnWPVGb6-VjTe0Vr-TuruPVKW4kJ0Zg%40mail.gmail.com?utm_medium=email&utm_source=footer> > . > > -- > You received this message because you are subscribed to the Google Groups > "Sanathana dharma and science" group. > To unsubscribe from this group and stop receiving emails from it, send an > email to [email protected]. > To view this discussion visit > https://groups.google.com/d/msgid/sanathana-dharma-and-science/SA1PR84MB38487ABC3D2A36E340267FA3D54CA%40SA1PR84MB3848.NAMPRD84.PROD.OUTLOOK.COM > <https://groups.google.com/d/msgid/sanathana-dharma-and-science/SA1PR84MB38487ABC3D2A36E340267FA3D54CA%40SA1PR84MB3848.NAMPRD84.PROD.OUTLOOK.COM?utm_medium=email&utm_source=footer> > . > -- You received this message because you are subscribed to the Google Groups "Thatha_Patty" group. To unsubscribe from this group and stop receiving emails from it, send an email to [email protected]. To view this discussion visit https://groups.google.com/d/msgid/thatha_patty/CAL5XZor276%2BxcLt2KJ254SNfEnBhFLuCVd-ZSb7wnW%3De%2B3Wxxw%40mail.gmail.com.
